Novartis (NVS) to collaborate with Antares Therapeutics to discover, develop and commercialize small-molecule cancer therapies targeting historically difficult-to-drug oncology targets, Antares Therapeutics said Wednesday.
Antares said it will receive $105 million upfront and could earn up to $1.8 billion in option, development, regulatory and commercial milestone payments, plus tiered royalties on future sales.
Antares will lead early research on selected targets using its drug discovery platform, while Novartis will have rights to advance and commercialize resulting programs, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments